Literature DB >> 9989339

The pharmacokinetic principles behind scaling from preclinical results to phase I protocols.

I Mahmood1, J D Balian.   

Abstract

Extrapolation of animal data to assess pharmacokinetic parameters in humans is an important tool in drug development. Allometric scaling has many proponents, and many different approaches and techniques have been proposed to optimise the prediction of pharmacokinetic parameters from animals to humans. The allometric approach is based on the power function Y = aWb, where the bodyweight of the species is plotted against the pharmacokinetic parameter of interest on a log-log scale. Clearance, volume of distribution and elimination half-life are the 3 most frequently extrapolated pharmacokinetic parameters. Clearance is not predicted very well (error between predicted and observed clearance > 30%) using the basic allometric equation in most cases. Thus, several other approaches have been proposed. An early approach was the concept of neoteny, where the clearance is predicted on the basis of species bodyweight and maximum life-span potential. A second approach uses a 2-term power equation based on brain and body weight to predict the intrinsic clearance of drugs that are primarily eliminated by phase I oxidative metabolism. Most recently, the use of the product of brain weight and clearance has been proposed. A literature review reveals different degrees of success of improved prediction with the different methods for various drugs. In a comparative study, the determining factor in selecting a method for prediction of clearance was found to be the value of the exponent. Integration of in vitro data into in vivo clearance to improve the predictive performance of clearance has also been suggested. Although there are proponents of using body surface area instead of bodyweight, no advantage has been noted in this approach. It has also been noted that the unbound clearance of a drug cannot be predicted any better than the total body clearance (CL). In general, there is a good correlation between bodyweight and volume of the central compartment (Vc); hence, Vc does not face the same complications as CL. The relationship between elimination half-life (t 1/2 beta) and bodyweight across species results in poor correlation, most probably because of the hybrid nature of this parameter. When a reasonable prediction of CL and Vc is made, t 1/2 beta may be predicted from the equation t 1/2 beta = 0.693 Vc/CL.

Entities:  

Mesh:

Year:  1999        PMID: 9989339     DOI: 10.2165/00003088-199936010-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  52 in total

1.  Some fundamental considerations of the applications of pharmacokinetics to cancer chemotherapy.

Authors:  K B Bischoff
Journal:  Cancer Chemother Rep       Date:  1975 Jul-Aug

Review 2.  Extrapolation of animal toxicity to humans: interspecies comparisons in drug development.

Authors:  E M Voisin; M Ruthsatz; J M Collins; P C Hoyle
Journal:  Regul Toxicol Pharmacol       Date:  1990-10       Impact factor: 3.271

3.  Cyclosporine pharmacokinetics in rats and interspecies comparison in dogs, rabbits, rats, and humans.

Authors:  L Sangalli; A Bortolotti; L Jiritano; M Bonati
Journal:  Drug Metab Dispos       Date:  1988 Sep-Oct       Impact factor: 3.922

4.  LIFE HISTORY VARIATION IN PRIMATES.

Authors:  Paul H Harvey; T H Clutton-Brock
Journal:  Evolution       Date:  1985-05       Impact factor: 3.694

5.  Remoxipride: pharmacokinetics and effect on plasma prolactin.

Authors:  G Movin-Osswald; M Hammarlund-Udenaes
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

6.  Predicting toxicokinetic parameters in humans from toxicokinetic data acquired from three small mammalian species.

Authors:  K Bachmann
Journal:  J Appl Toxicol       Date:  1989-10       Impact factor: 3.446

7.  Interspecies differences and scaling for the pharmacokinetics of xanthine derivatives.

Authors:  Y Tsunekawa; T Hasegawa; M Nadai; K Takagi; T Nabeshima
Journal:  J Pharm Pharmacol       Date:  1992-07       Impact factor: 3.765

8.  Correlation of unbound plasma clearances of fifteen extensively metabolized drugs between humans and rats.

Authors:  W L Chiou; F H Hsu
Journal:  Pharm Res       Date:  1988-10       Impact factor: 4.200

9.  Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humans.

Authors:  J W Paxton; S N Kim; L R Whitfield
Journal:  Cancer Res       Date:  1990-05-01       Impact factor: 12.701

10.  Interspecies comparison of acivicin pharmacokinetics.

Authors:  J P McGovren; M G Williams; J C Stewart
Journal:  Drug Metab Dispos       Date:  1988 Jan-Feb       Impact factor: 3.922

View more
  10 in total

1.  Metabolism and disposition of 3,4-methylenedioxymethamphetamine ("ecstasy") in baboons after oral administration: comparison with humans reveals marked differences.

Authors:  Melanie Mueller; Amy K Goodwin; Nancy A Ator; Una D McCann; George A Ricaurte
Journal:  J Pharmacol Exp Ther       Date:  2011-04-14       Impact factor: 4.030

2.  Allometric scaling of pegylated liposomal anticancer drugs.

Authors:  Whitney P Caron; Harvey Clewell; Robert Dedrick; Ramesh K Ramanathan; Whitney L Davis; Ning Yu; Margaret Tonda; Jan H Schellens; Jos H Beijnen; William C Zamboni
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-08-24       Impact factor: 2.745

3.  Genetically engineered cancer models, but not xenografts, faithfully predict anticancer drug exposure in melanoma tumors.

Authors:  Austin J Combest; Patrick J Roberts; Patrick M Dillon; Katie Sandison; Suzan K Hanna; Charlene Ross; Sohrab Habibi; Beth Zamboni; Markus Müller; Martin Brunner; Norman E Sharpless; William C Zamboni
Journal:  Oncologist       Date:  2012-09-19

Review 4.  The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development.

Authors:  D K Walker
Journal:  Br J Clin Pharmacol       Date:  2004-12       Impact factor: 4.335

5.  Projection of exposure and efficacious dose prior to first-in-human studies: how successful have we been?

Authors:  Christine Huang; Ming Zheng; Zheng Yang; A David Rodrigues; Punit Marathe
Journal:  Pharm Res       Date:  2007-09-25       Impact factor: 4.200

6.  PEGylated DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor.

Authors:  Laetitia Devy; Shafaat A Rabbani; Mark Stochl; Mary Ruskowski; Ian Mackie; Laurent Naa; Mark Toews; Reinoud van Gool; Jie Chen; Art Ley; Robert C Ladner; Daniel T Dransfield; Paula Henderikx
Journal:  Neoplasia       Date:  2007-11       Impact factor: 5.715

Review 7.  Reinforcing effects of methylenedioxy amphetamine congeners in rhesus monkeys: are intravenous self-administration experiments relevant to MDMA neurotoxicity?

Authors:  William E Fantegrossi
Journal:  Psychopharmacology (Berl)       Date:  2006-03-23       Impact factor: 4.530

8.  The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects.

Authors:  Elizabeth Cm de Lange
Journal:  Fluids Barriers CNS       Date:  2013-02-22

9.  Preclinical Modeling of Tumor Growth and Angiogenesis Inhibition to Describe Pazopanib Clinical Effects in Renal Cell Carcinoma.

Authors:  A Ouerdani; H Struemper; A B Suttle; D Ouellet; B Ribba
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-11-03

10.  Pharmacokinetics and interspecies allometric scaling of ST-246, an oral antiviral therapeutic for treatment of orthopoxvirus infection.

Authors:  Adams Amantana; Yali Chen; Shanthakumar R Tyavanagimatt; Kevin F Jones; Robert Jordan; Jarasvech Chinsangaram; Tove C Bolken; Janet M Leeds; Dennis E Hruby
Journal:  PLoS One       Date:  2013-04-18       Impact factor: 3.752

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.